Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-26 | Craig Johnson has served as a director of Heron since 2014. ... The Audit Committee is composed of three directors: Messrs. Johnson, Poyhonen and Waage. ... The Compensation Committee is composed of three directors: Messrs. Poyhonen, Johnson and Tang. ... The Governance Committee is composed of three directors: Messrs. Tang, Johnson and Waage. ... The following table includes compensation for services provided by our non-employee directors for the year ended December 31, 2018: Craig Johnson total compensation $365,594. |
| 2020-04-23 | Craig Johnson has served as a director of Heron since 2014. ... The Audit Committee is composed of three directors: Messrs. Davis, Johnson and Waage. ... The Compensation Committee is composed of three directors: Messrs. Davis, Johnson and Tang. ... The Governance Committee is composed of three directors: Messrs. Johnson, Tang and Waage. ... The following table includes compensation for services provided by our non-employee directors for the year ended December 31, 2019: ... Option Awards: $335,253 Fees Earned or Paid in Cash: $50,000 Total: $385,253. |
| 2021-04-22 | Craig Johnson has served as a director of Heron since 2014. Mr. Johnson has more than 25 years of experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. |
| 2022-04-25 | Craig Johnson has served as a director of Heron since 2014. The Board has concluded that Mr. Johnson should serve as a director based on his experience serving as a director of biotechnology companies and his expertise in financial management. |
| 2023-05-01 | Craig Johnson has served as a director of Heron since 2014. The Audit Committee is composed of three directors: Messrs. Johnson and Kotler and Ms. Rodriguez. Mr. Johnson serves as the Chair of the Audit Committee. ... The following table includes compensation for services provided by our non-employee directors for the year ended December 31, 2022: ... Craig Johnson $107,500 Fees Earned or Paid in Cash, $105,709 Stock Awards, $126,018 Option Awards, $339,227 Total. |
| 2024-04-29 | Craig Johnson has served as a director of Heron since 2014. He also serves as a director of Odonate, Inc. Mr. Johnson previously served as a director of Mirati Therapeutics, Inc. from 2013 until its acquisition by Bristol Myers Squibb in 2024, La Jolla Pharmaceutical Company from 2013 until its acquisition by Innoviva, Inc. in 2022, Decipher Biosciences, Inc. from 2015 to 2018, Adamis Pharmaceuticals Corporation from 2011 to 2014, and Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, he held various positions at MitoKor, Inc., concluding his service as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn. The Board has concluded that Mr. Johnson should serve as a director based on his experience serving as a director of biotechnology companies and his expertise in financial management. |
Data sourced from SEC filings. Last updated: 2025-12-06